METAGENOMI THERAPEUTICS INC
MGXNASDAQTrading Snapshot
- Day Range
- $1.20 – $1.22
- 52-Week Range
- $1.13 – $3.95
- Volume
- $2.61B
- Avg Volume
- $3.26B
- Shares Outstanding
- 37.6M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $25M
- Last Q Revenue
- $6M
- P/E Ratio
- —
- P/S Ratio
- 2.1x
- EPS (TTM)
- $-2.30
- Dividend Yield
- —
Why Investors Own MGX
- ✓High-growth profile — revenue up +25.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 66% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About METAGENOMI THERAPEUTICS INC
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.
Metagenomi Q2 EPS $(0.73) Misses $(0.57) Estimate, Sales $(257.000K) Miss $2.960M Estimate
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.07 percent. This is a 35.19 percent decrease over losses of $(0.54) per share from the